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Abstract
Introduction Trials to test disease-modifying treatments for frontotemporal dementia are eagerly awaited and sensitive 
instruments to assess potential treatment effects are increasingly urgent, yet lacking thus far. We aimed to identify gene-
specific instruments assessing clinical onset and disease progression by comparing cognitive functioning between bvFTD 
patients across genetic mutations.
Methods We examined differences in 7 cognitive domains between bvFTD patients with GRN (n = 20), MAPT (n = 29) or 
C9orf72 (n = 31) mutations, and non-carriers (n = 24), and described longitudinal (M = 22.6 months, SD = 16.6) data in a 
subsample (n = 27).
Results Patients showed overall cognitive impairment, except memory recall, working memory and visuoconstruction. GRN 
patients performed lower on executive function (mean difference − 2.1; 95%CI − 4.1 to − 0.5) compared to MAPT and 
lower on attention compared to MAPT (mean difference − 2.5; 95%CI − 4.7 to − 0.3) and C9orf72 (mean difference − 2.4; 
95%CI − 4.5 to − 0.3). Only MAPT patients were impaired on delayed recall (mean difference − 1.4; 95%CI − 2.1 to − 0.7). 
GRN patients declined rapidly on attention and memory, MAPT declined in confrontation naming, whereas C9orf72 patients 
were globally impaired but remained relatively stable over time on all cognitive domains.
Discussion This study shows gene-specific cognitive profiles in bvFTD, which underlines the value of neuropsychological 
tests as outcome measures in upcoming trials for genetic bvFTD.
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Background
Frontotemporal dementia (FTD) includes a large spectrum 
of neurodegenerative disorders with a variable clinical 
presentation of either progressive behavioral and execu-
tive deficits (behavioral variant FTD [bvFTD]) or language 
dysfunction (primary progressive aphasia [PPA]), associ-
ated with prominent frontal and/or anterior temporal lobe 
degeneration [29]. bvFTD is the most common phenotype in 
the clinical spectrum and the neuropsychological profile is 
generally characterized by impaired executive function (e.g., 
planning, set shifting and working memory), social cogni-
tion (e.g., theory of mind, emotional processing), whereas 
memory and visuoconstruction are relatively spared in com-
parison to executive dysfunction [27]. However, it is becom-
ing increasingly clear that these cognitive impairments vary 
in severity and progression. Executive dysfunction may be 
absent or overshadowed by behavioral dysfunctions and/or 
significant episodic memory impairment can be present even 
at the earliest stages of the disease [13, 29]. Factors influenc-
ing the variety in cognitive impairments between patients 
with bvFTD are not yet understood.
In 20–30% of cases, FTD has an autosomal dominant 
pattern of inheritance (i.e., mutations in microtubule-asso-
ciated protein tau [MAPT], progranulin [GRN] genes, or 
a repeat expansion in chromosome 9 open reading frame 
72 [C9orf72] gene) [20]. GRN mutations often lead to a 
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prominent asymmetrical pattern of atrophy in the frontal, 
temporal and parietal lobes, and are associated with behavio-
ral deficits, apraxia and language disorders, most frequently 
resulting in a clinical diagnosis of bvFTD or non-fluent vari-
ant PPA (nfvPPA) and is often accompanied by parkinson-
ism [21, 29]. MAPT mutations show localized temporal lobe 
involvement associated with behavioral and semantic defi-
cits, resulting in bvFTD as the main phenotype, and is occa-
sionally accompanied by a parkinson-dominant phenotype 
with corticobasal syndrome (CBS) or progressive supranu-
clear palsy (PSP) syndrome [4, 29]. The atrophy associated 
with C9orf72 repeat expansion is rather diffuse, and as a 
result leads to a more widespread pattern of clinical and cog-
nitive features such as behavioral and executive impairment 
but also notable psychiatric features including psychosis and 
anxiety [1, 24]. This is usually accompanied by a clinical 
diagnosis of bvFTD and/or motor neuron disease (MND) 
[29]. Cognitive differences between genetic variants of FTD 
can, in part, be explained by the associated phenotypes (i.e., 
bvFTD or PPA). Yet, there is also a high variability in the 
profile of cognitive decline between patients with bvFTD. 
This might be due to the different atrophy patterns associated 
with each genetic mutation.
Implementation of clinical trials to test disease-modifying 
treatments for bvFTD is eagerly awaited and instruments that 
can signal clinical onset and measure potential longitudinal 
treatment effects are increasingly urgent. Although a small 
number of studies have presented comprehensive clinical 
descriptions of FTD patients with mutations in MAPT, GRN 
or C9orf72 [21, 24, 26, 33, 38], there are even less studies 
that concisely and elaborately describe the specific cogni-
tive profiles associated with each mutation or make direct 
comparisons between genetic variants. Investigating the dis-
tinct cognitive profiles between genetic variants of bvFTD 
will enable us to identify gene-specific sensitive cognitive 
outcome measures for signaling disease onset, tracking dis-
ease progression and measuring potential treatment effects 
in upcoming therapeutic trials.
We compared cognitive profiles cross-sectional in 
patients with bvFTD due to mutations in GRN, MAPT or 
C9orf72 and report patterns of cognitive decline in a subset 
of patients with follow-up data.
Methods
Participants
Patients were included in an ongoing genetic-epidemiolog-
ical study, after referral to the outpatient clinic of the Eras-
mus Medical Center between 1994 and 2018. We reviewed 
data of patients with a known pathogenic mutation in MAPT 
or GRN, or repeat expansion in C9orf72, who had a clinical 
diagnosis of bvFTD and underwent one or multiple neu-
ropsychological assessments (n = 81) [27]. Standardized 
work up consisted of a neurological and neuropsychological 
assessment, laboratory testing and brain imaging. Diagnosis 
was determined in a multidisciplinary consensus meeting 
of the FTD Expertise Center of the Erasmus MC University 
Medical Center, involving experienced neurologists, neu-
ropsychologists, neuroradiologists, geriatricians, and a care 
consultant according to established diagnostic criteria for 
bvFTD [27]. Patients were categorized into three subtypes 
based on their clinical presentation; disinhibited (e.g., loss 
of social manners, inappropriate and impulsive behavior), 
apathetic (e.g., lack of interests in life activities and/or inter-
actions with others, little motivation to undertake action) 
and stereotypic (e.g., pacing, picking, ritualistic behavior) 
[32]. For a separate analysis, patients with a GRN mutation 
were divided based on predominant left-sided (n = 10), right-
sided (n = 4) or generalized atrophy (n = 4) as described in 
the report of the radiologist. For two patients there was no 
report available. Twenty-four non-carrier participants that 
were part of an ongoing epidemiological study of Dutch 
pathologically confirmed genetic FTD families [FTD Risk 
cohort (FTD-RisC [8])], were used as a reference (matched 
for age, education and sex).
Neuropsychological assessment
As the standardized neuropsychological test battery under-
went some changes over the time period of 24 years, the 
protocol differed between patients. We only included tests 
with ten or more subjects in each group. Global cognitive 
functioning was screened with the Mini-Mental State Exam-
ination (MMSE) [10] and the Frontal Assessment Battery 
(FAB) [9]. For executive functioning we used the Trail mak-
ing Test (TMT) part B [7], Stroop Color Word Test (SCWT) 
interference card III [17], Modified Wisconsin Card Sorting 
Test (mWCST) [25], and Similarities of the Wechsler Adult 
Intelligence Scale III-NL (WAIS-III) [39]. For attention and 
concentration we used TMT part A [7], and the SCWT word 
reading (I) and color naming card (II) [17]. For language we 
used the Boston Naming Test (BNT) [18], and semantic and 
letter fluency. For episodic memory—immediate recall, we 
used the Rey Auditory Verbal Learning Test (RAVLT) Dutch 
version [37]—immediate recall trial, the Rivermead Behav-
ioral Memory Test (RBMT) [41] Dutch version – immedi-
ate recall, and the short version of the Visual Association 
Test (VAT) [23]. For episodic memory—delayed recall, we 
used the RAVLT Dutch version—delayed recall trial and 
the RBMT Dutch version—delayed recall trial. For work-
ing memory we used the total score of the WAIS-III Digit 
Span (forward upper limit 9; backward upper limit 8) [39]. 
For visuoconstruction we used the Clock Drawing test [30]. 
For the BNT, the VAT and Clock Drawing Test different 
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test versions were used (respectively, 15-item/30-item/60-
item, 12-item/24-item, 3-item/14-item). For these respective 
tests, the scores were extrapolated to match performance on 
the version with the maximum score. The TMT and SCWT 
scores were truncated to 300 s for patients that exceeded the 
time limit or were unable to complete the test. The mean was 
calculated for SCWT cards I and II, as both tests are meas-
ures of attention/processing speed. When patients underwent 
multiple neuropsychological assessments in a short period of 
time (≤ 4 months) we considered this as one baseline assess-
ment (n = 3); for tests that were performed at both assess-
ments, the score of the first assessment was included in the 
cross-sectional baseline analyses.
Statistical analyses
Statistical analyses were performed using SPSS Statistics 
21.0 (IBM Corp., Armonk, NY). To aid interpretation, we 
standardized all raw neuropsychological test scores by con-
verting them into z-scores (i.e., individual test score minus 
the mean of non-carriers, divided by the standard deviation 
(SD) of non-carriers). Composite domain scores constituted 
the mean of the z-scores for the tests within one domain (as 
described in Sect. 2.2). When a neuropsychological test was 
missing, the domain was calculated based on the remain-
ing test scores in that specific domain. On TMT A and B, 
SCWT card I + II and card III, WCST, and VAT, a log10 
transformation was applied to normalize the data. We set the 
significance level at p < 0.05 (2-tailed) across all compari-
sons. We compared demographic data with one-way analy-
ses of variance. We analyzed sex and subtype differences 
between groups using Pearson χ2 tests. Neuropsychological 
data between groups were analyzed by means of one-way 
analysis of covariance. For the comparison of each mutation 
carrier group to non-carriers we used age as a covariate, 
and performed planned contrasts between each mutation car-
rier group and non-carriers. We compared mutation carrier 
groups in pairwise comparisons with disease duration as an 
additional covariate. Additional analyses were performed to 
compare cognitive domains in GRN patients with a predomi-
nant left-sided, right-sided or generalized atrophy pattern. 
All post-hoc analyses were Bonferroni corrected for multi-
ple comparisons. Effect sizes (Cohen’s d) were calculated 
for the (significant) differences in test scores. According to 
Cohen’s Nomenclature [6] d > 0.80 indicates a large differ-
ence. A bias-corrected 95% confidence interval (CI) was 
calculated based on the standard error. The percentage over-
lap (%OL) in (significant) test scores between groups was 
also reported according to Zakzanis’ calculations [42]; d = 0 
equates to 100% overlap, d = 1.0 equates to 45% overlap and 
d = 3 equates to less than 5% overlap in group scores. In 
addition, we report a description of a subset of patients with 
longitudinal data both on composite cognitive domains and 
neuropsychological tests (as described in Sect. 2.2). Due 
to the small sample size, we did not perform longitudinal 
statistical analysis.
Results
Demographics
Demographic data are shown in Table 1. MAPT mutation 
carriers were significantly younger than the other mutation 
carrier groups. C9orf72 repeat expansion carriers were older 
and had a significantly longer disease duration than the other 
Table 1  Demographic features
Values indicate mean ± SD or n (%) unless otherwise specified
MAPT microtubule-associated protein tau, GRN progranulin, C9orf72 chromosome 9 open reading frame 72, NC non-carriers, dis disinhibited, 
apa apathetic, ster stereotypic, MMSE Mini-Mental State Examination, FAB Frontal Assessment Battery, n.s not significant
a Verhage Dutch educational system categorized into levels from 1 = less than 6 years of primary education to 7 = academic schooling
MAPT mutation 
carriers (n = 29)
GRN mutation car-
riers (n = 20)
C9orf72 mutation 
carriers (n = 31)
Non-carriers (n = 24) p Value Group differences
Age at baseline, y 52.6 ± 5.5 60.4 ± 7.4 62.1 ± 9.1 56.1 ± 5.7  < 0.01 MAPT < GRN = C9orf72
NC < C9orf72
Sex (% female) 10 (34.5%) 12 (57.1%) 13 (41.9%) 11 (45.8%) 0.6 n.s
Educational level a 
(median (IQR))
5 (2) 5 (2) 5 (2) 5 (0) 0.8 n.s
Disease duration, y 1.4 ± 2.0 1.0 ± 1.1 3.1 ± 2.7 NA  < 0.01 MAPT = GRN < C9orf72
Subtype
dis—apa—ster
9 15 5 6 14 0 6 21 3 NA 0.3 n.s
MMSE 25.9 ± 2.9 22.5 ± 6.3 26.5 ± 2.7 29.3 ± 0.8  < 0.01 GRN < MAPT < NC
GRN < C9orf72
FAB 14.7 ± 3.2 10.0 ± 4.7 13.9 ± 3.4 16.1 ± 1.7  < 0.01 GRN < MAPT = NC
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mutation carrier groups. GRN mutation carriers performed 
significantly lower on MMSE and FAB.
Cross‑sectional analysis—comparison 
to non‑carriers
Table 2 shows the baseline z-scores of neuropsychological 
tests for the three mutation carrier groups. Compared to 
non-carriers, all mutation carrier groups were significantly 
impaired on language, attention/mental processing speed 
and executive functioning, but not on working memory and 
visuoconstruction. Executive functioning was most sensi-
tive to differentiate GRN mutation carriers from non-carriers 
(mean difference − 5.1; 95%CI − 6.5 to 3.7, p < 0.01, d = 2.9, 
%OL = 8.8–7.2), whereas language was most sensitive to dif-
ferentiate C9orf72 (mean difference − 2.1; 95%CI − 2.8 
to − 1.3, p < 0.01, d = 2.0, %OL = 18.9) and MAPT muta-
tion carriers (mean difference − 2.3; 95%CI − 3.0 to − 1.6, 
p < 0.01, d = 1.8, %OL = 22.6) from non-carriers. On neu-
ropsychological test level this translated into logWCST 
being most sensitive to differentiate GRN mutation carriers 
from non-carriers (mean difference − 1.0; 95%CI − 1.4 to 
− 0.7, p < 0.01, d = 3.0, %OL = 7.2), RBMT direct (mean 
difference − 2.0; 95%CI − 2.9 to − 1.2, p < 0.01, d = 2.4, 
%OL = 13) and delayed (mean difference − 2.2; 95%CI 
− 3.1 to − 1.3, p < 0.01, d = 2.4, %OL = 13) recall were 
Table 2  Differences between genetic mutation carrier groups on neuropsychological tests within seven cognitive domains
Values indicate mean ± SD
Non-carriers were excluded as they had means of zero and SDs of one by definition
MAPT microtubule-associated protein tau, GRN progranulin, C9orf72 chromosome 9 open reading frame 72, BNT Boston Naming Test, TMT 
Trail Making Test, WCST Wisconsin Card Sorting Test, RAVLT Rey Auditory Verbal Learning Test, RBMT Rivermead Behavioral Memory 
Test, VAT Visual Association Test, n.s not significant
The p values constitute interaction terms of univariate analyses of covariance (corrected for age) (on z-scores and *log10 transformed data)
Domain MAPT mutation carriers n GRN mutation carriers n C9orf72 
mutation 
carriers
n p Value Group differences
Language − 2.2 ± 1.5 26 − 2.5 ± 1.4 20 − 2.3 ± 1.4 28  < 0.01 GRN = MAPT = C9orf72 < NC
 BNT60 − 2.4 ± 2.6 23 − 2.3 ± 2.5 17 − 2.1 ± 1.9 22  < 0.01 GRN = MAPT = C9orf72 < NC
 Semantic fluency − 2.5 ± 1.2 26 − 2.7 ± 1.3 20 − 2.6 ± 1.3 27  < 0.01 GRN = MAPT = C9orf72 < NC
 Letter fluency − 0.6 ± 1.3 17 − 2.2 ± 0.6 13 − 1.2 ± 0.8 18  < 0.01 GRN < MAPT = C9orf72 < NC
Attention and mental 
processing speed
− 1.2 ± 1.9 25 − 4.3 ± 4.1 18 − 2.1 ± 2.3 24  < 0.01 GRN < MAPT = C9orf72 < NC
 TMT A* − 0.8 ± 1.2 25 − 3.9 ± 4.1 18 − 2.3 ± 3.6 24  < 0.01 GRN < MAPT < NC
C9orf72 < NC
 SCWT card I and II* − 2.7 ± 3.2 21 − 4.9 ± 5.8 17 − 3.0 ± 1.6 19  < 0.01 GRN = MAPT = C9orf72 < NC
Executive functioning − 2.7 ± 2.5 25 − 5.3 ± 2.5 18 − 4.0 ± 2.6 24  < 0.01 GRN < MAPT < NC
C9orf72 < NC
 TMT B* − 2.3 ± 2.8 24 − 5.5 ± 2.7 18 − 3.8 ± 2.6 23  < 0.01 GRN < MAPT < NC
C9orf72 < NC
 SCWT card III* − 3.2 ± 4.0 20 − 7.7 ± 4.6 17 − 5.3 ± 3.4 19  < 0.01 GRN < MAPT < NC
C9orf72 < NC
 WCST concepts* − 1.6 ± 1.6 16 − 2.8 ± 0.6 14 − 1.1 ± 1.6 14  < 0.01 GRN < C9orf72 < NC
MAPT < NC
 WAIS-III Similarities − 1.6 ± 2.2 11 − 2.8 ± 1.4 10 − 1.8 ± 1.3 10  < 0.01 GRN = C9orf72 = MAPT < NC
Memory—learning − 3.3 ± 6.6 25 − 4.7 ± 6.1 18 − 3.0 ± 5.3 24 0.02 MAPT = GRN < NC
 RAVLT-learning − 1.1 ± 1.2 21 − 1.1 ± 1.8 14 − 1.4 ± 1.1 19  < 0.01 MAPT = C9orf72 = GRN < NC
 RBMT-learning − 2.1 ± 0.7 10 − 2.0 ± 1.0 10 − 1.7 ± 1.0 11  < 0.01 GRN = MAPT = C9orf72 < NC
 VAT* − 6.3 ± 10.7 12 − 10.6 ± 11.8 12 − 5.0 ± 9.4 16 0.02 GRN < NC
Memory—recall − 1.3 ± 1.3 24 − 1.0 ± 1.6 16 − 0.9 ± 1.2 22  < 0.01 MAPT < NC
 RAVLT-recall − 0.9 ± 1.3 21 − 0.7 ± 1.7 14 − 0.5 ± 1.1 19 0.05 MAPT < NC
 RBMT-recall − 2.2 ± 0.8 9 − 1.7 ± 1.0 10 − 1.6 ± 1.1 11  < 0.01 GRN = MAPT = C9orf72 < NC
Working memory − 0.4 ± 1.7 11 − 1.1 ± 2.2 8 − 1.2 ± 1.2 10 0.09 n.s
 WAIS-III Digit Span − 0.4 ± 1.7 11 − 1.1 ± 2.2 8 − 1.2 ± 1.2 10 0.09 n.s
Visuoconstruction − 0.7 ± 2.4 20 − 1.0 ± 1.6 18 − 1.2 ± 2.7 22 0.30 n.s
 Clock drawing − 0.7 ± 2.4 20 − 1.0 ± 1.6 18 − 1.2 ± 2.7 22 0.30 n.s
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most sensitive to differentiate MAPT mutation carriers from 
non-carriers, and logSCWT I and II was most sensitive to 
differentiate C9orf72 mutation carriers from non-carriers 
(mean difference 0.34; 95%CI 0.2–0.5, p < 0.01, d = 2.4, 
%OL = 13). Concerning memory, GRN (mean difference 
− 4.5; 95%CI − 7.6 to − 1.3, p = 0.02, d = 1.1, %OL = 41.1) 
and MAPT (mean difference − 3.8; 95%CI − 6.8 to − 0.8, 
p = 0.04, d = 0.7, %OL = 57) mutation carriers were equally 
impaired in immediate recall, also with significant impair-
ment in delayed recall in the latter group (mean difference 
− 1.4; 95%CI − 2.1 to − 0.7, p < 0.01, d = 1.2, %OL = 37.8). 
Analyses showed that C9orf72 repeat expansion (mean 
difference − 1.2; 95%CI − 2.0 to − 0.4, p = 0.01, d = 1.4, 
%OL = 31.9) and MAPT mutation (mean difference − 1.2; 
95%CI − 2.0 to − 0.5, p < 0.01, d = 1.0, %OL = 44.6) carriers 
were equally impaired on RAVLT—immediate recall, but in 
addition with significant impairment on RAVLT—delayed 
recall in the latter group (mean difference − 1.1; 95%CI 
− 1.8 to − 0.3, p = 0.02, d = 0.8, %OL = 52.6). GRN mutation 
carriers were only significantly impaired on the VAT (mean 
difference − 0.5; 95% CI − 0.8 to − 0.1, p = 0.02, d = 0.7, 
%OL = 57).
Cross‑sectional analysis—comparison 
between mutation carrier groups
On domain level, GRN mutation carriers could be differen-
tiated from MAPT mutation carriers by significantly lower 
attention and mental processing speed (mean difference 
− 2.5; 95%CI − 4.7 to − 0.3, p = 0.02, d = 1.0, %OL = 44.6), 
and executive functioning (mean difference − 2.1; 95%CI 
− 4.1 to − 0.5, p = 0.03, d = 1.1, %OL = 41.1) (Table 2). On 
test level, GRN mutation carriers performed significantly 
worse on letter fluency (mean difference − 1.3; 95%CI − 2.2 
to − 0.4, p < 0.01, d = 1.6, %OL = 26.9), TMT A (mean dif-
ference − 0.48; 95%CI − 0.1 to − 0.09, p = 0.02, d = 1.2, 
%OL = 37.8), TMT B (mean difference − 0.5; 95%CI − 0.1 
to − 0.9, p = 0.02, d = 1.1, %OL = 41.1), and SCWT card 
III (mean difference -0.4; 95%CI − 0.1 to − 0.8, p = 0.01, 
d = 0.7, %OL = 57). GRN mutation carriers could be dif-
ferentiated from C9orf72 repeat expansion carriers by sig-
nificant lower attention and mental processing speed (mean 
difference -2.4; 95%CI − 4.5 to − 0.3, p = 0.02, d = 0.7, 
%OL = 57). On test level, GRN mutation carriers performed 
significantly worse on letter fluency (mean difference 
− 1.1; 95%CI − 2.0 to − 0.3, p = 0.01, d = 1.3, %OL = 34.7) 
and WCST (mean difference − 0.6; 95%CI − 1.1 to -0.1, 
p = 0.02, d = 1.2, %OL = 37.8) compared to C9orf72 muta-
tion carriers. The other tests did not differentiate between 
mutation carrier groups. On domain level, GRN patients 
with predominant left-sided atrophy performed signifi-
cantly worse on language compared to GRN patients with 
predominant right-sided atrophy (mean difference − 2.3; 
95%CI − 4.3 to − 0.3, p = 0.02, d = 2.3, %OL = 13). There 
were no other significant differences between GRN mutation 
carriers with different atrophy patterns (see Supplementary 
material).
Within‑individual longitudinal trajectories 
of cognitive decline
We explored individual trajectories of cognitive decline in a 
subset of patients (n = 27) that underwent multiple neuropsy-
chological assessments (Fig. 1; Online Resource). Overall, 
GRN mutation carriers (n = 3) showed the largest decline of 
all mutation carrier groups in the first year after diagnosis. 
Specifically, these patients declined most on attention, men-
tal processing speed and memory. MAPT mutation carriers 
(n = 13) performed at an intermediate level between GRN 
and C9orf72 mutation carriers (n = 11) on all tests, but did 
not seem to decline more profoundly on a specific cogni-
tive domain compared to other domains. C9orf72 repeat 
expansion carriers showed the most stable trajectories with 
minimal decline on most domains. MAPT mutation carriers 
performed lower and declined most on the BNT, whereas 
GRN mutation carriers declined most on the TMT A and B 
(Online Resource). Although the RAVLT showed lower per-
formance in MAPT mutation carriers, a steeper decline over 
time was seen in GRN mutation carriers (Online Resource).
Discussion
This study demonstrated gene-specific neuropsychologi-
cal profiles within the clinical phenotype of bvFTD. The 
three mutation carrier groups were impaired on all cogni-
tive domains compared to non-carriers, except for working 
memory and visuoconstruction. Interestingly, patients with 
bvFTD could be differentiated according to genetic mutation 
both on cognitive domain level and on neuropsychological 
test level. Attention and mental processing speed, as well as 
executive functioning differentiated GRN from MAPT and 
C9orf72, and memory recall deficits seemed a distinctive 
feature of MAPT. Executive functioning was most sensitive 
to differentiate GRN mutation carriers from non-carriers, 
whereas language was most sensitive to differentiate MAPT 
and C9orf72 mutation carriers from non-carriers. Within-
individual trajectories indicated a more rapid decline on 
attention and memory in GRN mutation carriers and con-
frontation naming in MAPT in the first year after diagnosis, 
whereas C9orf72 repeat expansion carriers remained rela-
tively stable on all domains.
Studies in both presymptomatic [14] and symptomatic 
GRN mutation carriers [21] have shown impairment and/or 
decline in attention and mental processing speed. An expla-
nation for this decline (in fronto-subcortical functions) is the 
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extensive subcortical white matter lesions that are regularly 
seen in GRN mutation carriers [35]. The subcortical struc-
tures of the brain are thought to be especially important for 
information processing speed, and lesions in these structures 
have, therefore, been primarily associated with difficulties in 
attention and mental processing speed as well as executive 
functioning [5]. Interestingly, multiple neuroimaging studies 
have shown that GRN mutations are associated with marked 
asymmetrical cortical atrophy, with either left or right sided 
predominance [21]. It has been argued that these differ-
ences in patterns of neurodegeneration can be reflected in 
different cognitive profiles [21]. Additional analyses showed 
that GRN patients with more pronounced left-sided atrophy 
performed worse on language than patients with more pro-
nounced right-sided atrophy. This is unsurprising given that 
language processing is strongly left lateralized [11]. There 
were no other cognitive differences between patients with 
either primarily left-sided, right-sided or bilateral atrophy. 
Fig. 1  Within-individual trajec-
tories of cognitive decline on 
seven cognitive domains. NPA 
neuropsychological assessment, 
MAPT microtubule-associated 
protein tau, GRN progranulin, 
C9orf72 chromosome 9 open 
reading frame 72. Raw data for 
each neuropsychological test 
were first converted to z-scores 
by standardization to the 
baseline data of non-carriers. 
Composite cognitive domain 
scores were calculated. Each 
subplot presents the trajec-
tory on a specific cognitive 
domain. Data are available 
in: language (MAPT n = 9; 
GRN n = 3; C9orf72 n = 8); 
attention and mental process-
ing speed (MAPT n = 8; GRN 
n = 3; C9orf72 n = 8); executive 
functioning (MAPT n = 9; GRN 
n = 2; C9orf72 n = 8); working 
memory (MAPT n = 5; GRN 
n = 2; C9orf72 n = 6); memory 
learning (MAPT n = 7; GRN 
n = 3; C9orf72 n = 8); memory 
recall (MAPT n = 7; GRN n = 3; 
C9orf72 n = 7); visuoconstruc-
tion (MAPT n = 6; GRN n = 2; 
C9orf72 n = 7)
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Due to small sample sizes groups were not stratified accord-
ing to the pattern of neurodegeneration in the main part of 
the analyses, but grouping them together may have influ-
enced results (particularly language performance) for this 
group.
Within-individual trajectories in GRN mutation car-
riers showed a rapid decline on all cognitive domains in 
the first year after diagnosis. This rapid cognitive decline 
in GRN mutation carriers is also partially reflected by the 
finding that the majority of 17 cases that did not undergo 
repeated neuropsychological assessment were too severely 
cognitively impaired for testing at follow-up (i.e., residing in 
nursing home or unable to complete multiple neuropsycho-
logical tests at baseline). This finding is confirmed by other 
studies reporting a shorter disease duration [3] and more 
rapid changes following symptom onset in GRN mutation 
carriers [15]. The most profound decline was seen on atten-
tion/mental processing speed and memory. Memory prob-
lems have previously been described in GRN as a symptom 
characterizing progressed disease stages [16], although it 
could also be associated with the profound impairment in 
attention/mental processing speed [31].
MAPT mutation carriers were the only group impaired 
on both immediate and delayed recall at baseline, whereas 
GRN and C9orf72 mutation carriers were only impaired on 
immediate recall. This is in line with a previous study by 
Jiskoot et al. [16] that demonstrated significant decline on 
the RAVLT recall test in the presymptomatic stage of MAPT 
mutation carriers, with a further decline in participants that 
converted to symptomatic FTD during follow-up. This is 
further corroborated by the finding that the RBMT direct 
and delayed recall trials were most sensitive to differenti-
ate MAPT mutation carriers from non-carriers. Memory 
impairment has previously been described as a prominent 
symptom in patients with a MAPT mutation, possibly due 
to anteromedial temporal lobe atrophy that is often seen in 
MAPT [28]. This is an area that has been associated with 
defects in memory storage and consolidation, as is the case 
in for instance Alzheimer’s disease [34]. Another hypothesis 
that has been suggested is that memory deficits in bvFTD 
are a consequence of executive dysfunctioning (i.e., poor 
organization and lack of efficient learning strategies) due to 
prefrontal atrophy [14]. This suggests that memory impair-
ment differs between bvFTD patients depending on the 
underlying mutation and thus atrophy pattern, with MAPT 
mutation carriers demonstrating a “pure” memory impair-
ment resulting in lower performance on both immediate and 
delayed recall, whereas the immediate recall impairment in 
C9orf72 and GRN mutation carriers are potentially a conse-
quence of prefrontal and thus dysexecutive impairment, with 
relatively spared delayed recall performance.
In contrast to the findings of previous studies, MAPT 
mutation carriers in the current cohort did not show worse 
semantic functioning compared to GRN and C9orf72 muta-
tion carriers [26]. This discrepancy might be explained by 
the use of estimated 60-item versions of the BNT, a “seman-
tic” confrontation naming test, from 15-item BNT adminis-
trations. A validation study has shown that the 15-item BNT 
has lower sensitivity and diagnostic accuracy compared to 
the 60-item version of the BNT [12]. Another explanation 
might be that the nature of naming errors differed in each 
genetic variant. MAPT mutation carriers were relatively 
more impaired on BNT and semantic fluency compared to 
letter fluency, whereas GRN performed equally impaired on 
all language tests, suggesting different underlying mecha-
nisms (e.g., semantic problems versus dysexecutive control) 
(e.g., [36]. We included all fluency tasks in the language 
domain, but it has been previously demonstrated that fluency 
also involves other cognitive functions such as executive 
functioning and semantic memory. [36, 40]. Furthermore, 
within-individual trajectories showed that MAPT mutation 
carriers declined most on the BNT. It might also be pos-
sible that the occurrence of semantic impairments become 
more prominent in MAPT in a later stage of the disease 
[28], as anterior medial temporal lobe atrophy progresses, 
an area that has been linked to semantic naming errors in for 
instance Alzheimer’s disease [2] and is known to also dete-
riorate bilaterally in patients with a MAPT mutation [28].
Patients with a C9orf72 repeat expansion showed a wide-
spread and non-progressive pattern of cognitive impairment 
in language, attention/mental processing speed, executive 
functioning and immediate recall and no distinctive cogni-
tive impairment compared to GRN and MAPT mutation car-
riers. This cognitive profile is corroborated by studies indi-
cating that the neurodegenerative process associated with the 
C9orf72 repeat expansion is also widespread, with degenera-
tion in the frontal and temporal cortices but also subcortical 
and cerebellar regions [24]. It has been demonstrated that the 
first brain changes start to emerge already in early adulthood 
but do not evolve, suggesting that they reflect an abnormal 
neurodevelopmental trajectory rather than early neurodegen-
eration [22]. This possibly also explains the slowly progres-
sive bvFTD cases that have, in particular, been associated 
with the C9orf72 repeat expansion [19], and were also seen 
in our within-individual trajectories. One theory suggests 
that neuropsychiatric symptoms represent the clinical pro-
drome of bvFTD in C9orf72 repeat expansion carriers, with 
cognitive deterioration occurring only in progressed disease 
stages [22].
Overall, results show that it is possible to distinguish 
between genetic variants of bvFTD using specific neuropsy-
chological domains and tests. This enables the identification 
of sensitive tests for signaling disease onset and predicting 
disease progression in clinical practice and could inform 
future therapeutic trials in selecting clinical endpoints to 
monitor treatment response. The former could be helpful in 
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providing psycho-education and counseling to the patient 
and caregiver on the expected clinical presentation and dis-
ease course. Moreover, selection of the most sensitive tests 
per genetic defect enables shortening of the neuropsycho-
logical test battery thereby relieving patient burden [16]. 
Executive tasks, such as letter fluency, and tasks for atten-
tion and mental processing speed, such as TMT and SCWT, 
were most sensitive to detect GRN-associated FTD, whereas 
memory recall deficits seem a promising marker in MAPT-
associated FTD. There does not appear to be a specific 
cognitive domain/test that can differentiate C9orf72 from 
other genetic variants, possibly due to the widespread neu-
rodegenerative process affecting multiple cognitive domains 
equally and the slow progression. Importantly, though this 
study shows statistical differences between mutation carri-
ers groups, there is still a considerable percentage of over-
lap on all cognitive domains and tests, with letter fluency 
having the lowest %OL between groups (26.9–34.7%OL). 
In addition, GRN mutation carriers performed relatively 
worse on all cognitive tests, possibly due to an altogether 
greater disease severity. Although we corrected for disease 
duration in our analyses, a reliable instrument for disease 
severity (e.g., FTD-CDR) was lacking. Similarly, explora-
tory longitudinal descriptions provided valuable informa-
tion on rate of cognitive decline with indeed rapid cognitive 
decline in GRN, but slow progression in C9orf72 and MAPT 
showing intermediate decline. Taking this together, results 
should be interpreted carefully. We report several clear dif-
ferences between genetic mutations, but given the relatively 
wide range of cognitive impairments (i.e., multiple domains 
affected) found in our patient sample, and the high percent-
age of overlap between patient groups, it remains challeng-
ing to identify a gene-specific cognitive profile in individual 
patients. Our results should be viewed as guidance for select-
ing clinical endpoints in future therapeutic trials rather than 
recommendations for the ‘best’ neuropsychological test to 
be used.
The current longitudinal descriptions should be carefully 
interpreted as sample sizes are small. Further limitations 
are the changes in neuropsychological test protocol with 
different tests and test versions used over time during the 
extended time of the study. In addition, we did not include 
tasks measuring social cognition, a key feature in diagnosing 
bvFTD [27], as social cognitive tasks were only added to 
the standard neuropsychological assessment in our memory 
clinic since 2012, resulting in too small sample sizes for 
the current analysis (n < 10 in each group). A more clear 
dissociation between attention/mental processing speed and 
executive functioning tasks could have been made by analyz-
ing the inter-relationship between TMT A and B, and SCWT 
II and III. However, for several patients who were unable 
to complete the test, we truncated the score to 300 s. These 
patients typically already had a much higher completion 
time on TMT A or SCWT II, and calculating the ratio would, 
therefore, have resulted in optimizing the ratio-score specifi-
cally for those patients that were too cognitively impaired to 
complete the test.
This study presents a large cohort of genetic bvFTD 
patients, including three major genetic causes of FTD, with 
unique neuropsychological data covering a wide variety of 
tests in seven cognitive domains. We provide evidence of 
gene-specific cognitive profiles within patients with bvFTD 
and provide recommendations for the use of specific tests to 
assess gene-specific clinical onset and disease progression. 
This is important information for future clinical trials tar-
geting specific pathologies as clinical endpoints to monitor 
treatment response are increasingly urgent.
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